BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hurel Corporation Appoints EMD Millipore Executive Iwona Kelley as Chief Business Officer


4/23/2013 12:50:39 PM

North Brunswick, NJ, April 23, 2013 -- Hurel Corporation, (“Hurel”), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of Iwona Kelley, M.A., as Chief Business Officer. Ms. Kelley joins Hurel from EMD Millipore, and will be responsible for leading Hurel’s business, marketing strategy and client operations as the Company prepares for the commercial launch of its HurelStatic and HurelFlow products, which together improve the predictive reliability and over-all efficiency of pre-clinical drug development, reporting to Hurel CEO Robert Freedman.

At EMD Millipore, Ms. Kelley served as Biosciences Division District Manager, responsible for serving the life sciences communities in the North East United States, including the Boston/Cambridge bioplex. During her sixteen-year career with the Millipore family of companies, she held positions of progressively increasing authority for sales, domestic and international sales management, marketing strategy, and customer relations. Ms. Kelley began her career at Upstate Biotechnology, moving to Serologicals Corporation when Serologicals acquired Upstate in 2004. Her Millipore career began when Millipore acquired Serologicals in 2007, and continued when EMD, a subsidiary of Merck KGaA, the global chemical concern headquartered in Darmstadt, Germany, acquired Millipore in 2010.

“Iwona Kelley has put together a remarkable record of business development over the course of her extensive career,” said Hurel CEO Robert Freedman. “By staying really attuned to the needs of her customers, Iwona has demonstrated her talent for achieving rapid sales growth, exceeding sales targets and, in multiple instances, successfully launching first-to-market instrumentation, reagents, and software used in the Late Discovery and Pre-clinical Development stages of drug development. We are fortunate to have her at Hurel.”

Ms. Kelley’s broad product portfolios have included proprietary cell-based assays and analyzers, kinase panels, stem cells, flow cytometry instrumentation, and multiplex protein assay instrumentation, among many others. She received her Masters’ Degree in Biology from Harvard University and holds a Bachelors’ Degree in Biology from Holy Cross.

Ms. Kelley will remain based in Boston.

About Hurel

Hurel Corporation, based in North Brunswick, NJ and Beverly Hills, CA, is a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms that are used by major pharmaceutical research organizations in pre-clinical drug development, as well as in the toxicological testing of industrial materials and consumer products.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES